Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
182- CUR,  RES,  GI,    Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, LAPC-4
p38↓, MKP5↑, TNF-α↓, COX2↓, NF-kB↓,
183- CUR,    Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3
AR↓, AP-1↓, NF-kB↓, CBP↓,
169- CUR,    Curcumin inhibits the expression of vascular endothelial growth factor and androgen-independent prostate cancer cell line PC-3 in vitro
- in-vitro, Pca, PC3
VEGF↓,
168- CUR,    Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism
- in-vitro, Pca, PC3
Akt↓, mTOR↓, AMPK↑, TAp63α↑, TumCP↓,
6238- CUSP9,    A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3
- Trial, GBM, NA
toxicity↓, TrxR↓, ROS↓, TumCI↓, TumCMig↓, TumCA↓, MMP2↓, MMP9↓, COX2↓, ALDH↓, TumAuto↑, P-gp↓, eff↑,
6235- CUSP9,    Exhaustive in vitro evaluation of the 9-drug cocktail CUSP9 for treatment of glioblastoma
- in-vitro, GBM, NA
tumCV↓, NF-kB↓, HH↓, 5HT↓,
6236- CUSP9,  EP,    Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro
- in-vitro, GBM, U251
Apoptosis↑, MOMP↓, Casp2↑, Bcl-2↓, Mcl-1↓, eff↑, OCR↓, OXPHOS↓, TumCMig↓,
6237- CUSP9,    CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide
- NA, GBM, NA
PI3K↓, Akt↓, ROS↑, NF-kB↓, TNF-α↓, TLR2↓, other↓, TrxR↓, STAT3↓, MMPs↓, COX1↓, COX2↓, CA↓, ALDH↓, P-gp↓, HH↓, 5LO↓, mTOR↓, CycD3↓, Proteasome↓, other↓, MMP2↓, MMP9↓, ALDH↓, Copper↓,
6234- CUSP9,    In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma
- Human, GBM, NA
TumCP↓, Apoptosis↑, TumCMig↓, tumCV↓, TumCG↓, cl‑Casp3↑,
6233- CUSP9,    A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs CUSP9 by the International Initiative for Accelerated Improvement of Glioblastoma Care
- Review, GBM, NA
other↝, QoL↑,
6239- CUSP9,    The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy
- in-vitro, GBM, NA
eff↑, tumCV↓, CSCs↓, Akt↓, mTOR↓, STAT↓,
6240- CUSP9,    A Pilot Clinical Study of CUSP9v3: Nine Repurposed Drugs Combined With Temozolomide for the Treatment of Recurrent Glioblastoma
- Human, GBM, NA
toxicity↝,
6241- CUSP9,    RECURRENT GLIOBLASTOMA: INITIAL EXPERIENCES WITH COMPASSIONATE-USE CUSP9v3/v4
- Trial, GBM, NA
eff↑,
1910- CUSP9,    A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care
- Analysis, GBM, NA
Dose↝, QoL↑, Dose↝,
16- Cyc,  RES,    Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis
- in-vitro, GC, SGC-7901
HH↓, Gli1↓, EMT↓, N-cadherin↓, E-cadherin↑, Snail↓, TumCI↓, TumMeta↓,
6249- Cyc,    Cyclopamine tartrate, an inhibitor of Hedgehog signaling, strongly interferes with mitochondrial function and suppresses aerobic respiration in lung cancer cells
- in-vitro, NSCLC, A549 - in-vitro, NSCLC, H1299
HH↓, OCR↓, TumCP↓, Apoptosis↑, ROS↑, MMP↑, mtDam↑,
6242- Cyc,    The teratogenic Veratrum alkaloid cyclopamine inhibits Sonic hedgehog signal transduction
- in-vivo, Nor, NA
*Shh↓,
6243- Cyc,    Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened
- Study, Var, NA
AntiTum↑, HH↓, Smo↓,
6244- Cyc,    Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours
- in-vivo, Var, NA
HH↓, TumCG↓,
6245- Cyc,    Blockade of Hedgehog Signaling Inhibits Pancreatic Cancer Invasion and Metastases: A New Paradigm for Combination Therapy in Solid Cancers
- vitro+vivo, PC, NA
HH↓, Snail↓, E-cadherin↑, EMT↓, TumCI↓, ChemoSen↑, TumMeta↓, ALDH↓, eff↑,
6246- Cyc,    Cyclopamine is a novel Hedgehog signaling inhibitor with significant anti-proliferative, anti-invasive and anti-estrogenic potency in human breast cancer cells
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
HH↓, TumCP↓, TumCCA↓, TumCI↓, NF-kB↓, MMP2↓, MMP9↓, ERα/ESR1↓, cycD1/CCND1↓,
6247- Cyc,    Sonic Hedgehog Pathway Contributes to Gastric Cancer Cell Growth and Proliferation
- vitro+vivo, GC, MKN45
Shh↓, TumCP↓, TumCCA↓, Apoptosis↓, TumCG↓, cycD1/CCND1↓,
6248- Cyc,    The Hedgehog Inhibitor Cyclopamine Reduces β-Catenin-Tcf Transcriptional Activity, Induces E-Cadherin Expression, and Reduces Invasion in Colorectal Cancer Cells
- in-vitro, CRC, NA
HH↓, Apoptosis↑, Slug↓, Snail↓, Twist↓, EMT↓, β-catenin/ZEB1↓, E-cadherin↑, TumCI↓,
6250- Cyc,    Dose- and route-dependent teratogenicity, toxicity, and pharmacokinetic profiles of the hedgehog signaling antagonist cyclopamine in the mouse
- in-vivo, Nor, NA
*HH↓, *other↑,
6251- Cyc,    I only have eye for ewe: the discovery of cyclopamine and development of Hedgehog pathway-targeting drugs
- Review, Var, NA
HH↓,
6252- Cyc,    Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance
- Review, Var, NA
*BioAv↓, Smo↓, HH↓, eff↑,
6264- Cyste,    Different inhibition characteristics of intracellular transglutaminase activity by cystamine and cysteamine
- Review, Nor, NA
*TG2/TGase↓, eff↑,
6263- Cyste,    Mechanism for the inhibition of transglutaminase 2 by cystamine
- Study, Nor, NA
*neuroP↑, TG2/TGase↓,
6262- Cyste,    A Randomized Controlled Crossover Trial with Delayed-Release Cysteamine Bitartrate in Nephropathic Cystinosis: Effectiveness on White Blood Cell Cystine Levels and Comparison of Safety
- Trial, Nor, NA
*eff↑,
6261- Cyste,    A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis
eff↑, eff↑,
6260- Cyste,    A novel sustained‐release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers
- Trial, Nor, NA
*toxicity?,
6259- Cyste,    Therapeutic Applications of Cysteamine and Cystamine in Neurodegenerative and Neuropsychiatric Diseases
- Review, AD, NA - Review, Park, NA
*ROS↓, *neuroP↑, *BDNF↑, *NRF2↑, *BBB↑, *HSPs↑, *GSH↑, *TG2/TGase↓, Aβ↓,
6258- Cyste,    Cystamine and cysteamine as inhibitors of transglutaminase activity in vivo
- Review, NA, NA
*TG2/TGase↓,
6257- Cyste,    Cystamine induces AIF-mediated apoptosis through glutathione depletion
- vitro+vivo, Var, NA
AIF↑, GSH↓, neuroP↑,
6256- Cyste,    Transglutaminase 2 expression levels regulate sensitivity to cystamine plus TRAIL-mediated apoptosis
- in-vitro, Kidney, Caki-1
TG2/TGase↓, necrosis↑, selectivity↑,
6255- Cyste,    Cysteamine Suppresses Cancer Cell Invasion and Migration in Glioblastoma through Inhibition of Matrix Metalloproteinase Activity
- in-vitro, GBM, NA
MMPs↓, MMP2↓, MMP9↓, MMP14↓, TumCI↓, TumCMig↓, Dose↓,
4333- Cyste,    Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription
- vitro+vivo, AD, NA
*NRF2↑, *ARE↑, *neuroP↑, *BDNF↑, *GSH↑,
4332- Cyste,    Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases
- in-vivo, Park, NA - in-vivo, HD, NA
*neuroP↑, *other↝, *other↝,
4331- Cyste,    Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase
- in-vivo, HD, NA - NA, AD, NA
*BDNF↑, *neuroP↑, *TG2/TGase↓,
1871- DAP,    Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth
- in-vitro, AML, U937 - in-vivo, AML, NA
TumCP↓, Apoptosis↑, TumCG↓, PDK1↓, cl‑PARP↑, Bcl-xL↓, Bcl-2↓, Beclin-1↓, ATG3↓, PI3K↓, Akt↓, eff↑,
6592- DAS,    Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- Trial, CML, NA
Dose↝, other↝, OS↑,
6588- DAS,    Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies
Src↓, ABL1↓,
6591- DAS,    Dasatinib in solid tumors
- Review, Var, NA
Src↓, PDGF↓, ABL1↓, BioAv↝, Half-Life↝, Dose↝, eff↑,
6590- DAS,    Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells
- in-vitro, Pca, NA
Src↓, ABL1↓, BioAv↑, TumCG↓, Dose↓, TumCA↓, TumCMig↓, TumCI↓,
6589- DAS,    Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells
- in-vitro, CLL, NA
Src↓, ABL1↓,
6593- DAS,    Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors
TumCP↓, TumCI↓, TumMeta↓, eff↑, Src↓,
5194- DCA,    Metabolic modulation of glioblastoma with dichloroacetate
- vitro+vivo, GBM, NA
MMP↓, mt-ROS↑, Apoptosis↑, CSCs↓, Hif1a↓, P53↑, angioG↓, toxicity↓, PDKs↓,
5195- DCA,  Rad,    Dichloroacetate Radiosensitizes Hypoxic Breast Cancer Cells
- in-vitro, BC, 4T1 - in-vitro, BC, EMT6
PDKs↑, ROS↑, p‑PDH↓, ECAR↓, lactateProd↓, selectivity↓, RadioS↑,
5196- DCA,    Dichloroacetate induces apoptosis in endometrial cancer cells
- in-vitro, Var, NA
selectivity↑, MMP↓, survivin↓, Ca+2↓, P53↑, PDK1↓, PDH↑, Glycolysis↓, OXPHOS↑, ROS↑, Cyt‑c↑, Apoptosis↑, Casp↑, tumCV↓, PUMA↑,
5197- DCA,  5-FU,    Dichloroacetate attenuates hypoxia-induced resistance to 5-fluorouracil in gastric cancer through the regulation of glucose metabolism
- in-vitro, GC, NA
Glycolysis↓, ChemoSen↑, PDK1↓,

Showing Research Papers: 2751 to 2800 of 6604
Prev Page 56 of 133 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6604

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Copper↓, 1,   GSH↓, 1,   OXPHOS↓, 1,   OXPHOS↑, 1,   ROS↓, 1,   ROS↑, 4,   mt-ROS↑, 1,   TrxR↓, 2,  

Mitochondria & Bioenergetics ⓘ

ABL1↓, 4,   AIF↑, 1,   MKP5↑, 1,   MMP↓, 2,   MMP↑, 1,   mtDam↑, 1,   OCR↓, 2,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   ECAR↓, 1,   Glycolysis↓, 2,   lactateProd↓, 1,   PDH↑, 1,   p‑PDH↓, 1,   PDK1↓, 3,   PDKs↓, 1,   PDKs↑, 1,  

Cell Death ⓘ

Akt↓, 4,   Apoptosis↓, 1,   Apoptosis↑, 7,   Bcl-2↓, 2,   Bcl-xL↓, 1,   Casp↑, 1,   Casp2↑, 1,   cl‑Casp3↑, 1,   CBP↓, 1,   Cyt‑c↑, 1,   Mcl-1↓, 1,   MOMP↓, 1,   necrosis↑, 1,   p38↓, 1,   Proteasome↓, 1,   PUMA↑, 1,   survivin↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 2,   other↝, 2,   tumCV↓, 4,  

Autophagy & Lysosomes ⓘ

ATG3↓, 1,   Beclin-1↓, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

P53↑, 2,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 2,   CycD3↓, 1,   TAp63α↑, 1,   TumCCA↓, 2,  

Proliferation, Differentiation & Cell State ⓘ

ALDH↓, 4,   CSCs↓, 2,   EMT↓, 3,   Gli1↓, 1,   HH↓, 11,   mTOR↓, 3,   PI3K↓, 2,   Shh↓, 1,   Smo↓, 2,   Src↓, 5,   STAT↓, 1,   STAT3↓, 1,   TumCG↓, 5,  

Migration ⓘ

5LO↓, 1,   AP-1↓, 1,   CA↓, 1,   Ca+2↓, 1,   E-cadherin↑, 3,   MMP14↓, 1,   MMP2↓, 4,   MMP9↓, 4,   MMPs↓, 2,   N-cadherin↓, 1,   PDGF↓, 1,   Slug↓, 1,   Snail↓, 3,   TG2/TGase↓, 2,   TumCA↓, 2,   TumCI↓, 8,   TumCMig↓, 5,   TumCP↓, 7,   TumMeta↓, 3,   Twist↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   Hif1a↓, 1,   VEGF↓, 1,  

Barriers & Transport ⓘ

P-gp↓, 2,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 1,   COX2↓, 3,   NF-kB↓, 5,   TLR2↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

5HT↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,   ERα/ESR1↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   BioAv↝, 1,   ChemoSen↑, 2,   Dose↓, 2,   Dose↝, 4,   eff↑, 12,   Half-Life↝, 1,   RadioS↑, 1,   selectivity↓, 1,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

AR↓, 1,   ERα/ESR1↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,   neuroP↑, 1,   OS↑, 1,   QoL↑, 2,   toxicity↓, 2,   toxicity↝, 1,  
Total Targets: 118

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

ARE↑, 1,   GSH↑, 2,   NRF2↑, 2,   ROS↓, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,   other↝, 2,  

Protein Folding & ER Stress ⓘ

HSPs↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

HH↓, 1,   Shh↓, 1,  

Migration ⓘ

TG2/TGase↓, 4,  

Barriers & Transport ⓘ

BBB↑, 1,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 3,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   eff↑, 1,  

Functional Outcomes ⓘ

neuroP↑, 5,   toxicity?, 1,  
Total Targets: 16

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page